- WEDNESDAY, MAY 21, 2014
MERCREDI 21 MAI 2014 - THURSDAY, MAY 22, 2014
JEUDI 22 MAI 2014 - FRIDAY, MAY 23, 2014
VENDREDI 23 MAI 2014
| WEDNESDAY, MAY 21, 2014 / MERCREDI 21 MAI 2014 | ||||
|
||||
The speakers reserve the right not to publish their presentations on the website www.isheid.com. |
||||
Les intervenants du Congrès se réservent le droit d'accepter la mise en ligne de leur présentation |
||||
| 09.00 10.00 |
WELCOME MESSAGE /MESSAGE DE BIENVENUE
|
|||
| 10.00 11.00 |
THIRTY YEARS OF DISCOVERIES IN HIV /30 ANS DE DÉCOUVERTES SUR LE VIH
|
|||
|
||||
| Ten Big Mistakes we Did / Les 10 Grandes Erreurs Réalisées | ||||
 |
Stefano VELLA, Instituto Superiore di Sanita, Roma − Italy | |||
| Ten Big Challenges Ahead / Les 10 Grands Défis à Venir | ||||
|
Mark WAINBERG, McGill University, Montreal − Canada | |||
|
||||
| 11.30 13.00 |
MANAGING ANTIRETROVIRAL THERAPY - PART I /GESTION DES TRAITEMENTS ANTIRÉTROVIRAUX - PARTIE 1
|
|||
|
||||
| New ARV Drugs / Nouvelles Molécules Antirétrovirales | ||||
|
Roy GULICK, Weill Medical College of Cornell University, New-York − USA | |||
| First Line Therapy in 2014 / Traitement de Première Ligne en 2014 | ||||
| Mark NELSON, Chelsea and Westminster Hospital, London − UK | ||||
| Switch Strategies in 2014 / Stratégies de Changement en 2014 | ||||
|
Daniel PODZAMCZER, Hospital Universitari de Bellvitge, Barcelona − Spain | |||
| 01 - Clinical impact of Ultra Deep Versus Sanger Sequencing detection of minority mutations on HIV-1 Drug Resistance genotype interpretation after virological failure | ||||
|
Authors: Sofiane MOHAMED (1,4), Guillaume PENARANDA (1), Dimitri GONZALEZ (2), Claire CAMUS (1), Hacène KHIRI (1), Ronan BOULME (2), Chalom SAYADA (2), Patrick PHILIBERT (3), Daniel OLIVE (4), Philippe HALFON (1,3) (1) Alphabio Laboratory (2) Advanced Biological Laboratories (ABL), Luxembourg − Luxembourg (3) European Hospital, Marseille − France (4) Paoli Calmettes Institute, Cancer research center, Marseille − France | |||
| 02 - First-line Therapy with LPV/r vs NVP and 2 NRTIs in a Developing Country: W144 of a Randomized Trial |
||||
|
Authors: Nathan CLUMECK, Claude MWAMBA, Kabamba KABEYA, Vincent CALVEZ, Serge MATANDA, Dolorès VAIRA, Gilles PEYTAVIN, Coca NECSOI, Marc DELFORGE, David KADIEBWE, Chantal MILOLO, Joe ILUNGA, Liévin KAPEND Saint-Pierre University Hospital, Brussels − Belgium |
|||
|
||||
| 13.00 14.00 |
REGARDS CROISÉS SUR LA SEMAINE « FLASHTEST » DE DÉPISTAGE PAR TROD HORS LES MURS |
|||
|
||||
| Bilan national de la semaine Flashtest et focus en région PACA | ||||
|
Patricia ENEL, COREVIH Paca Ouest Corse, Marseille − France | |||
| Retours sur la participation de « Trodeurs » expérimentés | ||||
|
Geoffrey COUSIN, Association AIDES, Marseille − France | |||
| Retour d’expérience de nouveaux « Trodeurs » | ||||
|
Florence NICOLAÏ-GUERBE, SIS Animation, Marseille − France | |||
| 14.00 15.30 |
HIV AS A CHRONIC DISEASE /LE VIH COMME MALADIE CHRONIQUE
|
|||
|
||||
| Transitioning HIV-infected Youth into Adult Health Care / Passage du Suivi VIH Pédiatrique à l’Adulte | ||||
|
Rana CHAKRABORTY, Emory University, Atlanta − USA | |||
| Chronic Inflammation and Pathogenesis / Rôle Pathogénique de l’Inflammation Chronique | ||||
|
Frank MIEDEMA, University Medical Center, Utrecht − The Netherlands | |||
| Aging with HIV / Vieillissement et VIH | ||||
|
Patrick MALLON, University College of Dublin, Dublin − Ireland | |||
| The Cascade of HIV Care... and How to Improve it / La Cascade de la Prise en Charge du VIH... et les Moyens pour l’Améliorer | ||||
|
Julio MONTANER, British Columbia Center for Excellence in HIV/AIDS, Vancouver − Canada | |||
|
||||
| 16.00 17.00 |
KEYNOTE LECTURE | |||
| Managing HCV Infection: present and future / Gestion de l’infection à VHC : présent et futur | ||||
|
Jürgen ROCKSTROH, University of Bonn, Bonn − Germany | |||
|
||||
|
Industry-sponsored symposium The future is now: the new generation integrase inhibitor La nouvelle génération d’inhibiteurs de l’intégrase : c’est maintenant
|
|||
| What are the unmet patient needs today? / Quelles sont les attentes des patients aujourd’hui ? | ||||
| Alain LAFEUILLADE, Sainte Musse Hospital, Toulon − France | ||||
| A new Integrase Inhibitor: from Science to Clinical Practice / Nouvel Inhibiteur d’Intégrase : de la Science à la Pratique Clinique | ||||
| Mark NELSON, Chelsea and Westminster Hospital, London − UK | ||||
| Addressing patient needs: Discussion of clinical cases / Répondre aux attentes des patients : discussion autour de cas cliniques | ||||
| Alain LAFEUILLADE, Sainte Musse Hospital, Toulon − France Santiago MORENO, Ramon y Cajal Hospital, Madrid − Spain Mark NELSON, Chelsea and Westminster Hospital, London − UK |
||||
 |
||||
| THURSDAY, MAY 22, 2014 / JEUDI 22 MAI 2014 | |||||
The speakers reserve the right not to publish their presentation on the website www.isheid.com. |
|||||
Les intervenants du Congrès se réservent le droit d'accepter la mise en ligne de leur présentation |
|||||
| 08.30 10.30 |
ENDING THE HIV PANDEMIC /METTRE FIN À LA PANDÉMIE VIH
|
||||
|
|||||
| Improving Prevention and Early Diagnosis / Améliorer la Prévention et le Diagnostic Précoce | |||||
|
Virginie SUPERVIE, INSERM U943, Paris − France | ||||
| ART for Prevention: Opportunities, Challenges and Predictions / Traitement Antirétroviral pour la Prévention de la Transmission : opportunités, défis et prévisions | |||||
|
Myron S. COHEN, University of North Carolina, Chapel Hill − USA | ||||
| Prospects for an HIV Vaccine / Les perspectives d’un vaccin anti-VIH | |||||
|
Marc GIRARD, French National Academy of Medicine, Paris − France | ||||
| Implementation of TasP: challenges and opportunities / Le Traitement des Patients comme Prévention de la Transmission : défis et opportunités |
|||||
|
Joep LANGE, University of Amsterdam, Amsterdam − The Netherlands | ||||
| Ending the pandemic. When? How? / Mettre fin à la pandémie. Quand ? Comment ? | |||||
|
François DABIS, INSERM Research Center, Bordeaux − France | ||||
| 03 - Diversion of ARVs to Street Markets among Substance Using MSM: Potential Implications for TasP and PrEP Rollouts in the US | |||||
|
Authors: Steven P. KURTZ, Mance E. BUTTRAM, Hilary L. SURRATT Nova Southeastern University, Miami − USA | ||||
| 04 - Epithelial stem cells as mucosal antigen-delivering cells: A novel preventive approach | |||||
| Authors: Marie-Claire GAUDUIN, Robert WHITE, Nicole CHENCINER, Kathleen VINCENT, Patrice FROST, Philippe BLANCOU Texas Biomedical Research Institute, San Antonio − USA | |||||
|
|||||
| 11.00 12.30 |
MANAGING ANTIRETROVIRAL THERAPY - PART II /GESTION DES TRAITEMENTS ANTIRÉTROVIRAUX - PARTIE 2
|
||||
| ARV Regimen Choice and Co-morbidities / Choix des ARVs et Comorbidités | |||||
|
Barry PETERS, Saint-Thomas’ Hospital, London − UK | ||||
| Statin Use in Setting of HIV infection / Utilisation des Statines au cours de l’Infection VIH | |||||
|
Kenneth LICHTENSTEIN, National Jewish Health, Denver − USA | ||||
| Development of Long-acting ARV’s / Mise au Point d’ARVs à Libération Prolongée | |||||
|
Marta BOFFITO, Chelsea and Westminster Hospital, London − UK | ||||
| 05 - Four Days a Week and Less on Appropriate Antiviral Combinations Provided Long-Term Optimal Control over HIV-1 in 92 Patients | |||||
|
Authors: Jacques LEIBOWITCH, Dominique MATHEZ, Pierre DE TRUCHIS, Damien LEDU, Jean-Claude MELCHIOR, Guislaine CARCELAIN, Jacques IZOPET, John DAVID, Christian PERRONNE Raymond Poincaré Hospital, Marseille − France | ||||
| 06 - Synthetic HIV-1 matrix protein p17-based AT20-KLH therapeutic immunization in HIV-1- infected patients receiving antiretroviral treatment: A phase I safety and immunogenicity study | |||||
|
Authors: Arnaldo CARUSO, Marialuisa IARIA, Francesca CACCURI, Cinzia GIAGULLI, Simona FIORENTINI University of Brescia, Brescia − Italy |
||||
|
|||||
| 12.30 14.00 |
INDUSTRY-SPONSORED LUNCH SYMPOSIUM
|
||||
| Pros: Success of the Virological Eradication of HCV / Défenseur : Succès de l’Eradication virologique du VHC | |||||
|
Marc BOURLIÈRE, Saint-Joseph Hospital, Marseille − France | ||||
| Cons: Biological Challenges of HIV / Détracteur : Challenges Biologiques du VIH | |||||
 |
Isabelle POIZOT-MARTIN, Sainte Marguerite’s Hospital, Marseille − France | ||||
| Pros: New Approaches of HIV Eradication / Défenseur : Nouvelles Approches de l’Eradication du VIH | |||||
|
Antoine CHERET, University Hospital of Tourcoing, Infectious Diseases Department, Tourcoing − France | ||||
| Cons: Eradication Principles not put into Practice / Détracteur : Principes d’Eradication, mais pas dans la pratique | |||||
|
Roland LANDMAN, Bichat Hospital, Infectious Diseases Department, Paris − France | ||||
| 14.00 15.30 |
THREE HOT DEBATES IN HIV / TROIS DÉBATS BRÛLANTS SUR LE VIH
|
||||
|
|||||
| Should we Avoid Protease Inhibitors in First Lines due to their Lipid Side Effects? / Doit-on se Passer des Inhibiteurs de Protéase en Première Ligne du fait de leurs Effets Lipidiques ? | |||||
|
Pros: Jean-Pierre ROUTY, McGill University, Montreal − Canada | ||||
| Cons: Hans J. STELLBRINK, Sentrum, Hamburg ICH, Hamburg − Germany | |||||
| Is ART Suspension Never a Good Idea ? / L’arrêt du Traitement Antirétroviral est-il Toujours une Mauvaise Idée ? | |||||
|
Pros: Giuseppe TAMBUSSI, Vaccine and Immunotherapy Research Center, Milano − Italy | ||||
|
Cons: Guido POLI, San Raffaele Institute, Milano − Italy | ||||
| Is an HIV Vaccine Achievable ? / Peut-on Mettre au Point un Vaccin anti-VIH ? | |||||
|
Pros: Marc GIRARD, French National Academy of Medicine, Paris − France | ||||
|
Cons: Marie-Lise GOUGEON, Pasteur Institute, Paris − France | ||||
|
|||||
| 16.00 17.00 |
ORAL COMMUNICATIONS / COMMUNICATIONS ORALES
|
||||
|
|||||
| 07 - Long-term protection of hepatitis B vaccine in HIV-infected patients | |||||
| Authors: Raphaël BIEKRE, N. BEN LASFAR, N. VIGET, M. VALETTE, V. BACLET, T.HULEUX, E. SENNEVILLE, F. AJANA Infectious diseases department, Gustave Dron University Hospital, Tourcoing − France | |||||
| 08 - Innate sensing of viral infection by pDCs and regulation by IFN-α and HMGB1 of TRAIL expression on pDCs and NK cells | |||||
|
Authors: Héla SAIDI, Marlène BRAS, Pauline FORMAGLIO, Bruno CHARBIT, Jean-Philippe HERBEUVAL, Marie-Lise GOUGEON Pasteur Institute, Paris − France | ||||
| 09 - Structural and functional studies of HIV-1 pre-integration complexes | |||||
|
Authors: Marc RUFF (1), Nicolas LEVY (1), Sylvia EILER (1), Karine PRADEAU (1), Corinne CRUCIFIX (1), Aurélie SCHAETZEL (1), Robert DRILLIEN (1), Vincent PARISSI (2), Stéphane EMILIANI (3), Yves MELY (4), Patrick SCHULTZ (1) (1) Institute of Genetics and Molecular and Cellular Biology, Illkirch − France (2) University of Bordeaux, Laboratory of basic microbiology and pathogenicity, Bordeaux − France (3) Cochin Institute, Paris Descartes University, Paris − France (4) Faculty of Pharmacy, Laboratory of biophotonics and pharmacology, Illkirch − France |
||||
| 10 - Anti-SIV therapy in rhesus macaques with PLGA nanoparticles containing siRNAs | |||||
|
Authors: Luis D. GIAVEDONI, Valerie SEXTON, Vida L. HODARA, Laura M. PARODI, Lisa M. SMITH, Erwin GOLDBERG, Jill STEINBACH, W. Mark SALTZMAN Texas Biomedical Research Institute, San Antonio, Texas − USA |
||||
| 11 - Neonatal Macaque Model to Study Mycobacterium Tuberculosis Infection in Pediatric AIDS | |||||
|
Authors: Marie-Claire GAUDUIN, Magdalena CEPEDA, Mary SALAS, Robert WHITE, Melissa DE LA GARZA, Edward J. DICK, Michael OWSTON, Lisa Y. ARMITIGE Texas Biomedical Research Institute, San Antonio, Texas − USA |
||||
| 12 - Persistent production of an integrase-deleted HIV-1 variant with no resistance mutation and wild-type proviral DNA in a treated patient | |||||
|
Authors: Mary-Anne TRABAUD, L. COTTE, J. SAISON, C. RAMIERE, C. RONFORT, J.C. TARDY, P. ANDRE Hospices Civils of Lyon, Lyon − France |
||||
| 13 - Competition between HIV-1-encoded RRE RNA and miRNA-TRBP interactions alters RNA interference activity and gene expression | |||||
| Authors: Anne GATIGNOL (1), S.M. DANIELS (1), L. SINCK (1), N.J. WARD (1), C.E. MELENDEZ-PEÑA (1), R.J. SCARBOROUGH (1), I. AZAR (1), A. DAHER (1), K.M. PANG (2), J.J. ROSSI (2) (1) McGill University, Lady Davis Institute for Medical Research, Montreal − Canada (2) Beckman Research Institute of the City of Hope, Duarte, California − USA |
|||||
| 14 - IDO-induced immunosuppressive Tryptophan catabolism following primary HIV infection | |||||
| Authors: Mohammad-Ali Jenabian (1), Kishanda VYBOH (1), Ido KEMA (3), Cynthia KANAGARATHAM (2), Danuta RADZIOCH (2), Norbert GILMORE (1,2), Petronela ANCUTA (4,5), Cécile TREMBLAY (4,5), Jean-Pierre ROUTY (1,2) (1) Chronic Viral Illnesses Service of the McGill University Health Center, Montreal − Canada (2) Research Institute of the McGill University Health Center, Montreal − Canada (3) Department of Laboratory Medicine, University Medical Center, Groningen, University of Groningen − the Netherlands (4) University of Montreal, Department of microbiology and immunology, Montreal − Canada (5) CHUM Research Center, Montreal − Canada |
|||||
|
|||||
| 17.00 18.30 |
INDUSTRY-SPONSORED SYMPOSIUM
|
||||
| Today, to treat / Aujourd’hui traiter | |||||
|
Jürgen ROCKSTROH, University of Bonn, Bonn − Germany | ||||
| Tomorrow, to cure / Demain guérir | |||||
|
Jean-Pierre ROUTY, McGill University, Montreal − Canada | ||||
|
|||||
| FRIDAY MAY 23, 2014 / VENDREDI 23 MAI 2014 | ||||
The speakers reserve the right not to publish their presentation on the website www.isheid.com. |
||||
Les intervenants du Congrès se réservent le droit d'accepter la mise en ligne de leur présentation |
||||
| 08.30 10.30 |
THE HCV REVOLUTION /LA RÉVOLUTION VHC
|
|||
|
||||
| New anti-HCV Agents in the Pipeline / Les anti-VHC à Venir | ||||
|
Fabien ZOULIM, INSERM U1052, Lyon − France | |||
| Treatment of Hepatitis C in HIV Patients in the New DAA Era / Traitement de la Co-infection VIH-VHC à l’Ère des Antiviraux Spécifiques | ||||
|
Vicente SORIANO, Hospital Carlos III, Madrid − Spain | |||
| HCV Cure without Interferon / Guérison VHC sans Interféron | ||||
|
Marc BOURLIÈRE, Saint-Joseph Hospital, Marseille − France | |||
| 15 - Carcinovic Cohort: Prognostic factors of death in HIV/HCV coinfected patients with hepatocellular carcinoma (HCC) | ||||
|
Authors: Moana GELU-SIMEON, M. LEWIN, R. SOBESKY, M. OSTOS, T.BAYAN, F. BOUFASSA, L. MEYER, A. PERSOZ, E. TEICHER, H. FONTAINE, D. SALMON-CERON, O. SEROR, J.-C. TRINCHET, J.-C. DUCLOS-VALLEE Paul Brousse Hospital, Villejuif − France |
|||
| 16 - Liver fibrosis is strongly associated with an enhanced level of immunosuppressive Tryptophan catabolism independently of HCV viremia in ART-treated HIV/HCV co-infected patients | ||||
| Authors: Mohammad-Ali JENABIAN (1,2), Ido KEMA (3), Robert Paulino RAMIREZ (4), Sahar SAEED (5), Kathleen ROLLET (1), Kishanda VYBOH (1), Jean-Carlos TEJADA (6), Norbert GILMORE (1,2), Marina B. KLEIN (1,2), Jean-Pierre ROUTY (1,2) (1) Chronic Viral Illnesses Service of the McGill University Health Centre, Montreal, Quebec − Canada (2) Research Institute of the McGill University Health Centre, Montreal, Quebec − Canada (3) Department of Laboratory Medicine, University Medical Center, Groningen, University of Groningen − the Netherlands (4) School of Medicine, Research Department, Universidad Iberoamericana, Santo Domingo − Dominican Republic (5) Clinical Research Solutions, Division of Hematology, McGill University Health Centre, Montreal, Quebec − Canada (6) Instituto Dominicano de Estudios Virologicos, Santo Domingo − Dominican Republic |
||||
|
||||
| 11.00 12.00 |
INDUSTRY-SPONSORED SYMPOSIUM
|
|||
| From systematic PI/r regimens in first line… to / Des IP/r systématiques en 1ère ligne… à | ||||
| Jean-Jacques PARIENTI, University Hospital of Caen, Caen − France | ||||
| From a paternalist medicine… to a participative medicine / D’une médecine paternaliste… à une médecine participative | ||||
| Bertrand LEBOUCHE, McGill University Health Center, Montreal − Canada | ||||
| 12.30 14.00 |
A CURE FOR HIV ? / GUÉRIR DU VIH ?
| |||
| Update on HIV Reservoirs / Les Dernières Actualités sur les Réservoirs du VIH | ||||
|
Liang SHAN, John Hopkins University, Baltimore − USA | |||
| Pharmacological Approaches / Approches Pharmacologiques | ||||
|
Ole SCHMELTZ SØGAARD, University Hospital, Aarhus − Denmark | |||
| Gene Therapy and Bone Marrow Transplantation / Thérapie Génique et Greffe de Moelle | ||||
|
Joachim HAUBER, Heinrich Pette Institute – Leibniz Institute for Experimental Virology, Hamburg − Germany | |||
| 17 - Impact of the level of pre-ART CD4+ T cells in blood on the rectal HIV reservoir in longterm treated men (VIRECT study) | ||||
|
Authors: Delphine VERGNON-MISZCZYCHA (1), Alexandre GIRARD (1), Anne DEPINCE (1), Xavier ROBLIN (1,3), Emilie DEL TEDESCO (3), Anne FRESARD (2), Claire GUGLIELMINOTTI (2), Claude LAMBERT (4), Bruno POZZETTO (1,5), Frédéric LUCHT (1,2), Stéphane PAUL (1,4), Thomas BOURLET (1,5) (1) GIMAP, University of Saint-Etienne, France (2) Department of Infectious Diseases, University of Saint-Etienne − France (3) Department of Gastroenterology, University of Saint-Etienne − France (4) Immunology Unit, University of Saint-Etienne − France (5) Virology Unit, University of Saint-Etienne − France | |||
| 18 - Next-generation LTR-specific Tre-recombinase targets a majority of HIV-1 isolates | ||||
| Authors: Joachim HAUBER (1), Ilona HAUBER (1), Jan CHEMNITZ (1), Helga HOFMANN-SIEBER (1), Claus-Henning NAGEL (1), Niklas BESCHORNER (1), Carola SCHÄFER (1), Frank BUCHHOLZ (2) (1) Heinrich Pette Institute – Leibniz Institute for Experimental Virology, Hamburg − Germany (2) U niversity of Technology Dresden, University Hospital and Medical Faculty Carl Gustav Carus, Department of Medical Systems Biology, Dresden − Germany | ||||
| 19 - Towards gene therapy against HIV-1: New therapeutic target in Gag RNA accessible to ribozymes and RNA interference molecules | ||||
| Authors: Anne GATIGNOL (1), R.J. SCARBOROUGH (1), M.V. LEVESQUE (2), E. BOUDRIAS-DALLE (1), I.C. CHUTE (3), S.M. DANIELS (1), R.J. OUELLETTE (3), J.P. PERREAULT (2) (1) Lady Davis Institute for Medical Research, McGill University, Montréal, Quebec − Canada (2) Department of Biochemistry, Université de Sherbrooke, Sherbrooke, Quebec − Canada (3) Atlantic Institute of Research on Cancer, Moncton, New Brunswick − Canada |
||||
|
||||
| 14.00 15.30 |
EMERGING INFECTIOUS DIDISEASES / LES MALADIES INFECTIEUSES EMERGENTES
|
|||
|
||||
| HEPATITIS E / Hépatite E | ||||
| Harry DALTON, Royal Cornwall Hospital Trust, Truro − UK | ||||
| H7N9 Flu / Grippe H7N9 | ||||
|
Bruno LINA, Université Lyon 1, Lyon − France | |||
| MERS-CoV / Nouveau Coronavirus | ||||
|
Marcel A. MÜLLER, Institute of Virology, University of Bonn Medical Centre, Bonn − Germany | |||
| 20 - Clinical spectrum of post-chikungunya rheumatic musculoskeletal disorders and use of disease-modifying antirheumatic drugs to treat the chronic inflammatory entities: 6-year experience from Reunion Island | ||||
|
Authors: Emilie JAVELLE (1), Anne RIBERA (2,3), Isabelle DEGASNE (3), Catherine MARIMOUTOU (4), Fabrice SIMON (1) (1) Department of Infectious Diseases and Tropical Medicine, Laveran Military Teaching Hospital, Marseille − France (2) Rheumatology Office, Saint-Denis, La Réunion − France (3) Rheumatology Unit, Universitary Hospital Félix Guyon, Saint Denis, La Réunion − France (4) Army Center for Epidemiology and Public Health, Marseille − France |
|||
| 21 - Chikungunya infection: six years after, rheumatic morbidity and impaired quality of life persist! | ||||
|
Authors: Catherine MARIMOUTOU (2), Fabrice SIMON (1), J. FERRARO (1), Emilie JAVELLE (1) (1) Department of Infectious Diseases and Tropical Medicine, Laveran Military Teaching Hospital, Marseille − France (2) Army Center for Epidemiology and Public Health, Marseille − France |
|||
|
||||
| 15.30 15.45 |
ORAL COMMUNICATION AND POSTER AWARDS REMISE DU PRIX DE LA COMMUNICATION ORALE ET DU PRIX POSTER |
|||
| 15.45 16.45 |
RAPPORTEURS SUMMARY SESSION /SESSION DES RAPPORTEURS
|
|||
| HIV Prevention Summary / Résumé Prévention VIH | ||||
|
Jean-Pierre ROUTY, McGill University, Montreal − Canada | |||
| Clinical and Therapeutical aspects of HIV Summary / Résumé Données Cliniques et Thérapeutiques du VIH | ||||
|
Sabine KINLOCK, The Royal Free Hospital, London − UK | |||
| HCV Summary /Résumé VHC | ||||
|
Philippe HALFON, European Hospital, Marseille − France | |||
|
||||
|
||||